title: Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
abstract: Trial of intravitreal bevacizumab injection in 7 eyes of 4 infants with continued retinopathy of prematurity progression despite previous laser therapy was reported. Six of the eyes benefited from the therapy. Intravitreal bevacizumab injection may be an alternative therapy in progressive stage 3 retinopathy of prematurity despite laser photocoagulation.
authors.affiliation: Department of Ophthalmology, Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey.
authors.forename: Nazmiye
authors.initials: N
authors.lastname: Erol
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Gürsoy
authors.forename: Afsun
authors.initials: A
authors.lastname: Sahin
authors.forename: Hikmet
authors.initials: H
authors.lastname: Basmak
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005260:Female; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D058449:Intravitreal Injections; D017075:Laser Coagulation; D054023:Lasers, Semiconductor / Q000627:therapeutic use*; D008297:Male; D012178:Retinopathy of Prematurity / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab